Advertisement

Haemophilus b Oligosaccharide-CRM197 and Other Haemophilus b Conjugate Vaccines: A Status Report

  • David H. Smith
  • Dace Viceps Madore
  • Ronald J. Eby
  • Porter W. Anderson
  • Richard A. Insel
  • Cynthia L. Johnson

Abstract

Haemophilus influenzae type b (Haemophilus b) is a major cause of life-threatening and debilitating diseases in infants and young children. In the United States, it is the most common cause of bacterial meningitis, and also causes other invasive diseases, such as epiglottitis, septic arthritis, cellulitis, pneumonia and bacteremia. In 1985, United States Public Health officials estimated that, despite the availability of potentially effective antibiotics and medical care, up to 1 in every 200 children in the USA develops an invasive Haemophilus b disease before the age of five years (Cochi et al., 1985). The 1985 report by the U.S. National Academy of Science on establishing vaccine priorities in the United States (NRC, 1985) estimated the annual vaccine preventable costs of Haemophilus b disease to be approximately 425 million dollars, and ranked Haemophilus b vaccine among the highest priorities for needed new vaccines.

Keywords

Haemophilus Influenzae Young Infant Conjugate Vaccine Capsular Polysaccharide Diphtheria Toxin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahonkhai, V.I., Lukacs, L.J., Matthews, H., Vella, P. and Gerety, R.J. (1988), Continuing evaluation of safety and immunogenicity of Haemophilus b conjugate — N. meningitidis outer membrane protein vaccine (Hb-NOMP) (Abstract). Programs and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, 292, Abstract #1027.Google Scholar
  2. Ambrosino, D., Schreiber, J.R., Daum, R.S. and Siber, G.R. (1983), Efficacy of human hyperimmune globulin in prevention of Haemophilus influenzae type b disease in infant rats, Infect. Immun. 39, 709–714.PubMedGoogle Scholar
  3. Anderson, P. (1983), Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197, Infect. Immun. 39, 233–238.PubMedGoogle Scholar
  4. Anderson, P. and Insel, R.A. (1988), Prospects for overcoming maturational and genetic barriers to the capsular polysaccharide of Haemophilus influenzae type b, Vaccine, 6, 188–191.PubMedCrossRefGoogle Scholar
  5. Anderson, P., Pichichero, M., Edwards, K., Porch, C.R. and Insel, R.A. (1987), Priming and induction of Haemophilus influenzae type b capsular antibodies in early infancy by Dpo20, an oligosaccharide-protein conjugate vaccine, J. Pediatr. 111, 644–650.PubMedCrossRefGoogle Scholar
  6. Anderson, P., Pichichero, M.E., Insel, R.A., Betts, R., Eby, R. and Smith, D.H. (1986), Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant, J. Immunol. 137, 1181–1186.PubMedGoogle Scholar
  7. Anderson, P., Pichichero, M.E. and Insel, R.A. (1985), Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b, coupled with diphtheria toxoid or the toxin protein CRM197, J. Clin. Invest. 76, 52–59.PubMedCrossRefGoogle Scholar
  8. Anderson, P., Smith, D.H., Ingram, D.L., Wilkins, J., Wehrle, P.F. and Howie, V.M. (1977), Antibody to polyribophosphate of Haemophilus influenzae type b in infants and children: Effect of immunization of polyribophosphate, J. Infect. Dis. 136, S557–S562.Google Scholar
  9. Anderson, P. and Smith, D.H. (1977), Immunogenicity in weanling rabbits of a polyribophosphate complex from Haemophilus influenzae type b, J. Infect. Dis. 136, 5563–5570.Google Scholar
  10. Berkowitz, C.D., Ward, J.I., Meier, K., Hendley, J.O., Brunell, P.A., Barkin, R.A., Zahradnik, J.M., Samuelson, J. and Gordon, L. (1987), Safety and immunogenicity of Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children 15 to 24 months of age, J. Pediatr. 110, 509–514.PubMedCrossRefGoogle Scholar
  11. Blake, M.S., Lytton, E.J., Seiff, M.E. and Gotschlich, E.C. (1988), Studies on gonococcal Protein III, In: Bacterial-Host Cell Interaction (Alan R. Liss, Inc.) 85–97.Google Scholar
  12. Chu, C., Schneerson, R., Robbins, J.B. and Rastogi, S.C. (1983), Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide protein conjugates, Infect. Immun. 40, 245–256.PubMedGoogle Scholar
  13. Claesson, B.A., Trollfors, B., Lagergard, T., Taranger, J., Bryla, D., Otterman, G., Cramton, T., Yang, Y., Reimer, C.B., Robbins, J.B. and Schneerson, R. (1988), Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18 to 23 month old children, J. Pediatr. 112, 695–702.PubMedCrossRefGoogle Scholar
  14. Cochi, S.L., Broome, C.V. and Hightower, A.W. (1985), Immunization of U.S. children with Haemophilus influenzae type b polysaccharide vaccine, JAMA 253, 521–529.PubMedCrossRefGoogle Scholar
  15. Crisel, R.M., Baker, R.S. and Dorman, D.E. (1975), Capsular polymer of Haemophilus influenzae type b, J. Biol. Chem. 250, 4926.PubMedGoogle Scholar
  16. Edwards, K.M., Decker, M.D., Porch, C.R., Palmer, P. and Bradley, R. (1989), Immunization after invasive Haemophilus influenzae type b disease. Serologic response to a conjugate vaccine, Am. J. Dis. Child. 143, 31–33.PubMedGoogle Scholar
  17. Einhorn, M.S., Weinberg, G.A., Anderson, E.L., Granoff, P.D. and Granoff, D.M. (1986), Immunogenicity in infants of Haemophilus influenzae type b polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein, Lancet 2, 299–302.PubMedCrossRefGoogle Scholar
  18. Eskola, J., Käyhty, H., Peltola, H., Karanko, V., takelä, P.H., Samuelson, J. and Gordon, L.K. (1985), Antibody levels achieved in infants by course of Haemophilus influenzae type b polysaccharide/diphtheria toxoid conjugate vaccine, Lancet 1, 1184–1186.PubMedCrossRefGoogle Scholar
  19. Eskola, J., Peltola, H., Takala, A.K., Käyhty, H., Hakulinen, M., Karanko, V., Kela, E., Rekola, P., Rönnberg, P., Samuelson, J.S., Gordon, L.K. and Mäkelä, P.H. (1987), Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy, N. Engl. J. Med. 317, 717–722.PubMedCrossRefGoogle Scholar
  20. Eskola, J., Takala, A., Peltola, H. and Mäkelä, P.H. (1988), Clinical efficacy of the Haemophilus influenzae type b (Hib) capsular polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D) in Finland, (Abstract), Program and Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, 309, Abstract #1126.Google Scholar
  21. Farr, R.S. (1958), A quantitative immunochemical measure of the primary interaction between IBSA and antibody, J. Infect. Dis. 103, 239–262.PubMedCrossRefGoogle Scholar
  22. Fothergill, L.D. and Wright, J. (1933), Influenzal meningitis: The relation of age incidence to bactericidal power of blood against causal organism, J. Immunol. 24, 273–284.Google Scholar
  23. Gigliotti, F., Feldman, S., Wang, W.C., Day, S.W., Brunson, G. Immunization of young infants with sickle cell disease with a Haemophilus influenzae type b saccharide-diphtheria CRM197 protein conjugate vaccine, Journal of Pediatrics, (in press).Google Scholar
  24. Goebel, W.F. and Avery, O.T. (1931), Chemo-immunological studies on conjugated carbohydrate-proteins, V. The immunological specificity of an antigen prepared by combining one capsular polysaccharide of type 3 pneumococcus with foreign protein, J. Exp. Med. 54, 437–447.PubMedCrossRefGoogle Scholar
  25. Granoff, D.M. and Cates, K.L. (1985), Haemophilus influenzae type b polysaccharide vaccines, J. Pediatr. 107, 330–336.PubMedCrossRefGoogle Scholar
  26. Insel, R.A. and Anderson, P.W. (1986), Response to oligosaccharide-protein conjugate vaccine against Haemophilus influenzae b in two patients with IgG2 deficiency unresponsive to capsular polysaccharide vaccine, N. Engl. J. Med. 315, 499–503.PubMedCrossRefGoogle Scholar
  27. Käyhty, H., Mäkelä, O., Eskola, J., Peltola, H. and Saarinen, L. (1988a), Quantitative and qualitative characterization of antibody response in infants, children and adults to three Haemophilus influenzae type b (Hib) conjugate vaccines. (Abstract). In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, 292, Abstract #1026.Google Scholar
  28. Käyhty, H., Mäkelä, O. and Eskola, J. (1988b), Isotype distribution and bactericidal activity of antibodies after immunization with Haemophilus influenzae type b vaccines at 18 to 24 months of age, J. Infect. Dis. (in press).Google Scholar
  29. Käyhty, H., Peltola, H., Karanko, V. and Mäkelä, P.H. (1983), The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b, J. Infect. Dis. 147, 1100.PubMedCrossRefGoogle Scholar
  30. King, S.D., Ramlal, A., Wynter, H., Moodie, K., Castle, D., Kuo, J.S.C., Barnes, L. and Williams, C.L. (1981), Safety and immunogenicity of a new Haemophilus influenzae type b vaccine in infants under one year of age, Lancet 2, 705–709.PubMedCrossRefGoogle Scholar
  31. Lepow, M.L., Samuelson, J.S. and Gordon, L.K. (1985), Safety and immunogenicity of Haemophilus influenzae type b polysaccharide diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age, J. Pediatr. 106, 185–189.PubMedCrossRefGoogle Scholar
  32. Mäkelä, O., Peterfy, F., Outschoorn, I.G., Ritcher, A.W. and Seppälä, I. (1984), Immunogenic properties of α-(1–6)-dextran, its protein conjugates and conjugates of its breakdown products in mice, Scand. J. Immunol. 19, 541–550.Google Scholar
  33. Marburg, S., Jorn, D., Tolman, R.L., Arison, B., McCauley, J., Kniskern, P.J., Hagopian, A. and Vella, P.P. (1986), Bimolecular chemistry of macromolecules — synthesis of bacterial polysaccharide conjugates with Neisseria meningitidis membrane protein, J. Am. Chem. Soc. 108, 5282–5287.CrossRefGoogle Scholar
  34. National Research Council, New Vaccine Development Establishing Priorities, I Diseases of Importance in the United States, National Academy Press, Washington, D.C., (1985).Google Scholar
  35. Peltola, H., Käyhty, H., Sivonen, A. and Mäkelä, H. (1977), Haemophilus influenzae type b capsular polysaccharide vaccine in children 3 months to 5 years of age in Finland, Pediatrics 60, 730–737.PubMedGoogle Scholar
  36. Poolman, J.T., Timmermans, H.A.M., Hopman, C.T.P., Teerlink, T., VanVaught, P.A.M., Witvliet, M.H. and Beuvery, E.C. (1988), Comparison of meningococcal outer membrane protein vaccines solubilized with detergent or C polysaccharide, In: Gonococci and Meningococci, Poolman, J.T., Zanen, H.C., Meyer, T.F., Heckles, J.E., Melä, P.R.H., Smith, H. and Beuvery, E.C., eds. Kluwer Academic Publishers, Norwell, MA, 159–165.CrossRefGoogle Scholar
  37. Rice, P.A., Vayo, H.E., Tam, M.R. and Blake, M.S. (1986), Immunoglobulin G antibodies directed against protein III block killing of serum resistant Neisseria gonorrhoeae by immune sera, J. Exp. Med. 164, 1735–1748.PubMedCrossRefGoogle Scholar
  38. Santosham, M., Reid, R., Ambrosino, D.M., Wolff, M.C., Hill, J.A., Priehs, CC., Aspery, K.M., Garrett, S., Croll, L., Foster, S., Burge, G., Page, P., Zacher, B., Moxon, R., Chir, B. and Siber, G.R. (1987), Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin, N. Engl. J. Med. 317, 923–929.PubMedCrossRefGoogle Scholar
  39. Schneerson, R., Barrera, O., Sutton, A. and Robbins, J.B. (1980), Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates, J. Exp. Med. 152, 361–376.PubMedCrossRefGoogle Scholar
  40. Schneerson, R. Rodrigues, L.P., Parke, J.C. Jr., and Robbins, J.B. (1971), Immunity to disease caused by Haemophilus influenzae type b II, Specificity and some biological characteristics of “natural” infection-acquired and immunization-induced antibodies to the capsular polysaccharide of Haemophilus influenzae type b, J. Immunol. 107, 1081–1089.PubMedGoogle Scholar
  41. Smith, D., Peter, G., Ingram, D.L., Harding, A.L. and Anderson, P. (1973), Responses of children immunized with the capsular polysaccharide of Haemophilus influenzae type b, Pediatrics 52, 637–645.PubMedGoogle Scholar
  42. Uchida, T., Pappenheimer, A.M. Jr. and Harper, A.A. (1972), Reconstitution of diphtheria toxin from two nontoxic cross-reacting mutant proteins, Science 175, 901–903.PubMedCrossRefGoogle Scholar
  43. Ward, J.I., Brenneman, G., Letson, G., Heyward, W. and Alaska Vaccine Efficacy Trial Study Group. (1988a), Limited protective efficacy of an H. influenzae type b conjugate vaccine (PRP-D) in native Alaskan infants immunized at 2, 4 and 6 months of age, (Abstract), Program and abstract of the Interscience Conference on Antimicrobial Agents and Chemotherapy, 309, Abstract #1127.Google Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • David H. Smith
    • 1
  • Dace Viceps Madore
    • 1
  • Ronald J. Eby
    • 1
  • Porter W. Anderson
    • 2
  • Richard A. Insel
    • 2
  • Cynthia L. Johnson
    • 1
  1. 1.Praxis Biologics, Inc.RochesterUSA
  2. 2.University of Rochester Medical CenterRochesterUSA

Personalised recommendations